Group 1 - The core point of the article is the strategic cooperation agreement between Dongyangguang Pharmaceutical and Shenzhen Jingtai Technology to establish a joint venture focused on AI-driven drug development [1][2][3] Group 2 - The joint laboratory will be established to develop innovative drug pipelines, focusing on autoimmune diseases, utilizing AI-driven automation for a closed-loop R&D process [1] - The collaboration aims to develop a PB-PK predictive model that aligns with industry-leading commercial software, leveraging high-quality non-clinical data and AI algorithm capabilities [2] - A "Model as a Service" (MaaS) business model will be created, providing an AI supercomputing platform that opens collaboration results to academia and industry, transforming data assets and AI products into a service model [3]